Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.

By Gaynor J. Bates, S. Fox, Cheng Han, R. Leek, J. F. García, Adrian L. Harris, A. Banham. Journal of Clinical Oncology, 2006

1,192 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/cdc9cb13010c3a8106482c8d4a2c119ac037d4dd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Lisa M. Coussens
2. F. Balkwill
3. D. DeNardo
4. T. Hagemann
5. J. Barreto
6. D. Tawfik
7. George Coukos
8. M. Capasso

In Oncology

1. Lisa M. Coussens
2. D. DeNardo
3. F. Balkwill
4. J. Reis-Filho
5. T. Hagemann
6. A. Richardson
7. George Coukos
8. M. Capasso

Citations in the corpus

• Regulatory T cells exhibit distinct features in human breast cancer (2016, neutral): “Increased presence of Treg cells in breast tumor biopsies is associated with an invasive phenotype and diminished relapse-free as well as overall survival (Bates et al., 2006; Bohling and Allison, 2008; Ohara et al., 2009).”
• The tumor microenvironment at a glance (2012, background): “High numbers of Tregs in the TME correlate with worse prognosis in many types of cancer (Bates et al., 2006; Curiel et al., 2004; Hiraoka et al., 2006).”
• Systemic Immunity is Required for Effective Cancer Immunotherapy (2017, neutral): “The frequency of Tregs has been suggested as a negative prognostic feature for various tumors (Bates et al., 2006; Curiel et al., 2004).”
• T Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis (2012, background): “cancer (7), gastric cancer (8), and ovarian cancer (6, 9).”
• Clinical significance of tumor-infiltrating lymphocytes in breast cancer (2016, background): “However, HR breast cancer is the only breast cancer subtype where FOXP3 infiltrate predicts a worse survival [10, 21, 25].”
• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. (2015, background): “The presence of CD4 regulatory T cells (Treg) has been associated with both good and bad [10, 11, 12].”
• CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. (2013, neutral): “In BC, the majority of studies investigating CD4 + TIL have been focused on Tregs (68), with their increased presence linked with a poor prognosis in ER + disease (21, 69) but a good clinical outcome in ER – disease (70).”